Effect of Oral Tizanidine on Local-anesthetic Infiltration Pain during Epidural Catheterization
スポンサーリンク
概要
- 論文の詳細を見る
Purpose: Tizanidine is a clonidine derivative and has the same effects, such as sedation, anxiolysis and analgesic response. We evaluated the effect of tizanidine on infiltration pain during epidural catheterization. Methods: Forty patients scheduled to undergo epidural anesthesia in elective surgery were randomly allocated into two groups. The control group received placebo 60 minutes before arrival in the operating room, and the tizanidine group received 3 mg of oral tizanidine as premedication 60 minutes before arrival in the operating room. Every patient was measured heart rate and blood pressure before receiving placebo or premedication and after arrival in the operating room. After an epidural catheter was indwelled, the patients were questioned about the infiltrating pain of local anesthetic, and the degree was assessed by means of visual analog scale score (VAS score, 0∼100 mm). Results: Blood pressure in the operating room was significantly attenuated in the tizanidine group compared to the control group (148±21 mmHg vs 130±15 mmHg). Heart rate was not significantly different between the two groups. Rate-pressure product was significantly lower in the tizanidine group (11282±2960 vs 9592±2632). VAS score in the tizanidine group was significantly lower than that in the control group (P<0.001). Conclusion: It was possible to reduce the infiltration pain of local anesthetic during epidural catheterization by oral administration of 3 mg of tizanidine as premedication. Blood pressure and rate-pressure product in the operating room were also attenuated by receiving tizanidine. Therefore, we recommend premedication with tizanidine for patients undergoing epidural catheterization.
- 日本医科大学医学会の論文
日本医科大学医学会 | 論文
- わが国における腸チフスの疫学的考察--1973年〜1976年届出菌検出例を中心として
- 臨床および実験報告 二絨毛膜双胎妊娠における高年初産の検討
- 救急災害医学の確立と展望[含 略歴 研究業績] (定年退職教授記念講演会講演要旨)
- 臨床のために 関節リウマチの診断と治療
- TNFファミリーの制御による関節リウマチ治療の可能性 (特集 第15回公開「シンポジウム」(アレルギー・膠原病に対する新たな展開))